KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $13.7 million.

  • Xenon Pharmaceuticals' Share-based Compensation rose 540.69% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.2 million, marking a year-over-year increase of 1488.34%. This contributed to the annual value of $50.7 million for FY2024, which is 5666.93% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Share-based Compensation stood at $13.7 million for Q3 2025, which was up 540.69% from $13.7 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Share-based Compensation ranged from a high of $14.7 million in Q2 2024 and a low of $2.0 million during Q1 2021
  • Over the past 5 years, Xenon Pharmaceuticals' median Share-based Compensation value was $8.5 million (recorded in 2023), while the average stood at $8.1 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 11725.31% in 2022, then tumbled by 681.57% in 2025.
  • Xenon Pharmaceuticals' Share-based Compensation (Quarter) stood at $2.7 million in 2021, then soared by 114.86% to $5.8 million in 2022, then surged by 57.98% to $9.2 million in 2023, then soared by 48.1% to $13.6 million in 2024, then grew by 0.78% to $13.7 million in 2025.
  • Its Share-based Compensation stands at $13.7 million for Q3 2025, versus $13.7 million for Q2 2025 and $12.2 million for Q1 2025.